The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs
Open accessAbstract
INTRODUCTION: Targeting pathogenetic mechanisms, rather than essential processes, represents a very attractive alternative for the development of new antibiotics. This may be particularly important in the case of antimycotics, due to the urgent need for novel antifungal drugs and the paucity of selective fungal targets. The opportunistic pathogenic fungus Candida albicans is the main etiological agent of candidiasis, the most common human fungal infection. These infections carry unacceptably high mortality rates, a clear reflection of the many shortcomings of current antifungal therapy, including the limited armamentarium of antifungal agents, their toxicity and the emergence of resistance. Moreover, the antifungal pipeline is mostly dry. AREAS COVERED: This review covers some of the most recent progress toward understanding C. albicans pathogenetic processes and how to harness this information for the development of anti-virulence agents. The two principal areas covered are filamentation and biofilm formation, as C. albicans pathogenicity is intimately linked to its ability to undergo morphogenetic conversions between yeast and filamentous morphologies and to its ability to form biofilms. EXPERT OPINION: Filamentation and biofilm formation represent high value targets, yet are clinically unexploited, for the development of novel anti-virulence approaches against candidiasis. Although this has proved a difficult task despite increasing understanding at the molecular level of C. albicans virulence, there are some opportunities and prospects for antifungal drug development targeting these two important biological processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 4×
“However, in immune or otherwise compromised patients, and depending on the underlying host defect, it can cause a variety of infections that range from mucosal to life-threatening invasive candidiasis, having the ability to infect virtually every organ in the host [2].”
InfluentialPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“The seriousness of this problem is heightened by the fact that even with treatment using available antifungal agents, mortality rates lie in the 30 -- 50% range for these infected patients [2,9,10].”
Nonfilamentous C. albicans Mutants Are Avirulent
Lo, H.-J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., & Fink, G. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80358-x · Cited by 1,809
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578
Virulence factors of Candida albicans
Calderone, R. A., & Fonzi, W. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02094-7 · Cited by 1,331 · cited 2×
“Filamentation not only represents a virulence trait per se, but it is also coordinately regulated with other virulence factors, which are associated with cellular morphology [29,31,34].”
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Growth of Candida albicans hyphae
Sudbery, P. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2636 · Cited by 1,110 · cited 1×
“From studies to date, it is clear that this is a complex and highly orchestrated process, as signaling pathways may converge on separate or identical transcription factors, and transcription factors may converge themselves on common target genes to trigger expression of hyphaspecific genes [35].”
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055 · cited 2×
“albicans remains the fungal species most commonly associated with the formation of biofilms, and indeed, most clinical manifestations of candidiasis are linked to biofilm formation [75-79].”
Cited by
Oral Candidiasis: A Disease of Opportunity
Vila, T., Sultan, A. S., Montelongo-Jauregui, D., & Jabra-Rizk, M. A. (2020) · Journal of Fungi · doi:10.3390/jof6010015 · Cited by 537
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study
Lara, H. H., Romero-Urbina, D. G., Pierce, C., Lopez-Ribot, J. L., Arellano-Jiménez, M. J., & Jose-Yacaman, M. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0147-8 · Cited by 323
“These biofilms are typically surrounded by an exopolymeric substance (EPS) matrix [6] which effectively shelters the fungal cells against adverse environmental conditions, including host defense mechanisms and the action of antifungals [7].”
BackgroundSelf-citationPierce, C. G., Chaturvedi, A. K., Lazzell, A. L., Powell, A. T., Saville, S. P., McHardy, S. F., & Lopez-Ribot, J. L. (2015) · npj Biofilms and Microbiomes · doi:10.1038/npjbiofilms.2015.12 · Cited by 124
Self-citationLara, H. H., Guisbiers, G., Mendoza, J., Mimun, L. C., Vincent, B., Lopez-Ribot, J. L., & Nash, K. L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s151285 · Cited by 104
“In this study, we used a well-established phenotypic assay as reported by Pierce et al 44 and Pierce and Lopez-Ribot.”
Self-citationPhotodynamic therapy of oral Candida infection in a mouse model
Freire, F., Ferraresi, C., Jorge, A. O. C., & Hamblin, M. R. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.03.049 · Cited by 103
Metadata
- Authors
- Pierce, C. G., & Lopez-Ribot, J. L.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2013-06-06
- Volume
- 8
- Issue
- 9
- Pages
- 1117-1126
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2053501504
- Cited by
- 158
- References
- 37
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. https://app.cochat.ai/papers/10.1517/17460441.2013.807245
- The paper
- Pierce, C. G., & Lopez-Ribot, J. L. (2013). Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2013.807245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.